XML 32 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Revenues
 12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of rest-of-world (ROW) revenues relates to products sold in Europe.
Revenues were as follows (in millions):
Year ended December 31, 2020Year ended December 31, 2019Year ended December 31, 2018
U.S.ROWTotalU.S.ROWTotalU.S.ROWTotal
Enbrel® (etanercept)
$4,855 $141 $4,996 $5,050 $176 $5,226 $4,807 $207 $5,014 
Prolia® (denosumab)
1,830 933 2,763 1,772 900 2,672 1,500 791 2,291 
Neulasta® (pegfilgrastim)
2,001 292 2,293 2,814 407 3,221 3,866 609 4,475 
Otezla®(1)
1,790 405 2,195 139 39 178 — — — 
XGEVA® (denosumab)
1,405 494 1,899 1,457 478 1,935 1,338 448 1,786 
Aranesp® (darbepoetin alfa)
629 939 1,568 758 971 1,729 942 935 1,877 
KYPROLIS® (carfilzomib)
710 355 1,065 654 390 1,044 583 385 968 
Repatha® (evolocumab)
459 428 887 376 285 661 358 192 550 
Other products4,306 2,268 6,574 3,511 2,027 5,538 4,035 1,537 5,572 
Total product sales(2)
17,985 6,255 24,240 16,531 5,673 22,204 17,429 5,104 22,533 
Other revenues511 673 1,184 693 465 1,158 929 285 1,214 
Total revenues$18,496 $6,928 $25,424 $17,224 $6,138 $23,362 $18,358 $5,389 $23,747 

____________
(1)    Otezla® was acquired on November 21, 2019.
(2)    Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2020, 2019 and 2018.
In the United States, we sell primarily to pharmaceutical wholesale distributors that we utilize as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.
We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2020, 2019 and 2018. For the year ended December 31, 2020, on a combined basis, these customers accounted for 83% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):
Years ended December 31,
202020192018
AmerisourceBergen Corporation:
Gross product sales$14,743 $12,301 $12,091 
% of total gross revenues34 %33 %33 %
McKesson Corporation:
Gross product sales$13,779 $11,795 $11,434 
% of total gross revenues32 %31 %31 %
Cardinal Health, Inc.:
Gross product sales$7,332 $6,538 $7,475 
% of total gross revenues17 %17 %20 %
As of December 31, 2020 and 2019, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 74% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2020 and 2019, 28% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2020 and 2019, was not material.